Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511739 | 0.73 | GAA (0.42) | — | |
| SCHEMBL20510175 | 0.72 | — | — | |
| SCHEMBL6897115 | 0.68 | ALDH1A1 (0.44) | — | |
| SCHEMBL754295 | 0.67 | PREP (0.34) | — | |
| SCHEMBL19385937 | 0.67 | DUT (0.36) | DUT | |
| SCHEMBL20511807 | 0.65 | TP53 (0.37) | — | |
| SCHEMBL2599179 | 0.64 | MAPT (0.44) | DUT | |
| SCHEMBL16322121 | 0.63 | DUT (0.32) | DUT | |
| SCHEMBL17099909 | 0.63 | GSTP1 (0.37) | DUT | |
| SCHEMBL18739778 | 0.63 | IDO1 (0.32) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091438-B2 | Processes for the preparation of heterocyclic scaffolds from alpha enaminones | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-11091438-B2 | Processes for the preparation of heterocyclic scaffolds from alpha enaminones | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-20200079738-A1 | PROCESSES FOR THE PREPARATION OF HETEROCYCLIC SCAFFOLDS FROM ALPHA ENAMINONES | Yissum Research Development Company, of The Hebrew University of Jerusalem Ltd. (IL) | 2020-03-12 | — | — | US | disclosed |
| EP-3601227-A1 | PROCESSES FOR THE PREPARATION OF HETEROCYCLIC SCAFFOLDS FROM ALPHA ENAMINONES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018173058-A1 | PROCESSES FOR THE PREPARATION OF HETEROCYCLIC SCAFFOLDS FROM ALPHA ENAMINONES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079738-A1 | PROCESSES FOR THE PREPARATION OF HETEROCYCLIC SCAFFOLDS FROM ALPHA ENAMINONES | ENO1, SQLE, DHPS | DUT 576/4885 |
| US-11091438-B2 | Processes for the preparation of heterocyclic scaffolds from alpha enaminones | ENO1, SQLE, DHPS | DUT 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.